Comprehensive clinical trial delivery across Phase I–III with a focus on quality and efficiency.
Accelerate Your Asthma Research with Pre-Characterised Patient Cohorts
Accelerated Clinical Trial Recruitment
Access a pre-characterized, engaged cohort of asthma patients ready for rapid onboarding. Reduce recruitment timelines and screening failures with comprehensive baseline phenotyping across the full GINA 1-5 spectrum.
Comprehensive Patient Characterisation
Deep phenotyping and endotyping data including:
Lung function assessments (spirometry, FOT)
T2 inflammation biomarkers
Exacerbation history and triggers
Patient-reported outcomes (AQLQ, ACQ, AIRQ)
Real-world disease progression data
Respiratory pathogen surveillance
Real-World Evidence Generation
Track asthma evolution in natural settings with seasonal and environmental influences. Understand exacerbation triggers, disease control patterns, and treatment responses over time.
Focus on Under-represented Populations
MAPLE-UK helps address the critical gap in long-term studies by emphasizing GINA 1-3 patients, providing insights into mild to moderate asthma often overlooked in clinical research.
Robust Longitudinal Framework
Cohort Size: 250 participants (expandable per protocol)
Duration: 5-year follow-up period
Setting: Real-world, community-based asthma management
Full-day comprehensive assessments
Lung function testing (spirometry, forced oscillation technique)
Provocation tests and atopy screening
Haematology, biochemistry, and biomarker sampling
Healthcare resource utilization tracking
Quality of life and asthma control questionnaires
6 month Virtual Check-ins:
Home diary cards monitoring symptoms and cold perception
Peak expiratory flow (PEF) measurements
Asthma medication tracking
Asthma Control Questionnaire (ACQ)
Real-time assessment during colds and exacerbations
Home lung function measurements
Respiratory pathogen sampling with nasal swabs
Symptom and medication diary cards
Core Assessments:
Spirometry and forced oscillation technique (FOT) using Thorasys Tremoflo C-100
Fractional exhaled nitric oxide (FeNO) using Niox Vero
Exacerbation history and trigger identification
Comorbidity assessment and risk factor analysis
Socioeconomic and environmental factor evaluation
Pharmaceutical & Biotech Companies:
Diagnostic & Device Manufacturers:
Academic Institutions:
Whether you're developing novel biologics, validating diagnostic tools, or seeking trial-ready cohorts, MAPLE-UK provides the flexibility, depth, and scientific rigor to support your goals.
Pre-characterized asthma patients for clinical trials through MAPLE UK a 5-year longitudinal study providing comprehensive phenotyping & real-world evidence
The study includes balanced recruitment across the full GINA 1-5 spectrum, with particular emphasis on GINA 1-3 patients who are underrepresented in long-term asthma research.
The pre-characterized cohort enables rapid screening and enrollment, significantly reducing typical recruitment timelines. Contact us to discuss your specific timeline requirements.
